No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNYm | 1,763 | 2,073 | 2,609 | 2,000 | 1,969 | 1,846 | N/A | N/A |
| Operating profit | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CNYm | 12 | 13 | 15 | 6 | 15 | 7 | N/A | N/A |
| EPS reported | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CNYm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CNY | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Daqing Huake Company Limited, founded in 1998 and headquartered in Daqing, China, operates primarily in the chemical sector within the country. The company specializes in the research, manufacturing, and distribution of petrochemicals and various fine chemical products. Its extensive chemical offerings include heavy and light aromatics, crude compounds such as isopentene, isoprene, and pentadiene, industrial acetonitrile, dicyclopentadiene, ethylene tar, hydrogenated pentene, light-colored petroleum resins, and intermittent liquid-phase bulk polypropylene powder. Beyond chemicals, Daqing Huake also produces a range of plastic items, notably specialized polypropylene materials for woven bag coatings and polyethylene insulation for communication cables, as well as a selection of medical and health-related goods. The company maintains an international presence, exporting its diverse product lines to approximately 20 countries and regions worldwide, including significant markets in Europe, Southeast Asia, and North America.
Similar companies
- Zhejiang Dayang Biology Technology Co.,Ltd.
- Wuxi Honghui New Materials Technology Co., Ltd.
- Ningxia Yinglite Chemicals Co., Ltd
- Maoming Petro-Chemical Shihua Co., Ltd
- Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd
- Shanxi Huayang New Material Co.,Ltd.
- PT Unggul Indah Cahaya Tbk
- Jiangsu Lanfeng Bio-chemical Co.,Ltd
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Daqing Huake Company Limited (000985.SZ)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Daqing Huake Company Limited, founded in 1998 and headquartered in Daqing, China, operates primarily in the chemical sector within the country. The company specializes in the research, manufacturing, and distribution of petrochemicals and various fine chemical products. Its extensive chemical offerings include heavy and light aromatics, crude compounds such as isopentene, isoprene, and pentadiene, industrial acetonitrile, dicyclopentadiene, ethylene tar, hydrogenated pentene, light-colored petroleum resins, and intermittent liquid-phase bulk polypropylene powder. Beyond chemicals, Daqing Huake also produces a range of plastic items, notably specialized polypropylene materials for woven bag coatings and polyethylene insulation for communication cables, as well as a selection of medical and health-related goods. The company maintains an international presence, exporting its diverse product lines to approximately 20 countries and regions worldwide, including significant markets in Europe, Southeast Asia, and North America.
- Zhejiang Dayang Biology Technology Co.,Ltd.
- Wuxi Honghui New Materials Technology Co., Ltd.
- Ningxia Yinglite Chemicals Co., Ltd
- Maoming Petro-Chemical Shihua Co., Ltd
- Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd
- Shanxi Huayang New Material Co.,Ltd.
- PT Unggul Indah Cahaya Tbk
- Jiangsu Lanfeng Bio-chemical Co.,Ltd